Topalian, S.L.; Taube, J.M.; Anders, R.A.; Pardoll, D.M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer, 2016, 16(5), 275-287.
[http://dx.doi.org/10.1038/nrc.2016.36] [PMID: 27079802]

Kyi, C.; Postow, M.A. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett., 2014, 588(2), 368-376.
[http://dx.doi.org/10.1016/j.febslet.2013.10.015] [PMID: 24161671]

Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.M.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbé, C.; Peschel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipili-mumab in patients with metastatic melanoma. N. Engl. J. Med., 2010, 363(8), 711-723.
[http://dx.doi.org/10.1056/NEJMoa1003466] [PMID: 20525992]

Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J-F.; Testori, A.; Grob, J-J.; Davidson, N.; Rich-ards, J.; Maio, M.; Hauschild, A.; Miller, W.H., Jr; Gascon, P.; Lotem, M.; Harmankaya, K.; Ibrahim, R.; Francis, S.; Chen, T-T.; Humphrey, R.; Hoos, A.; Wolchok, J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med., 2011, 364(26), 2517-2526.
[http://dx.doi.org/10.1056/NEJMoa1104621] [PMID: 21639810]

McDermott, D.F.; Atkins, M.B. PD-1 as a potential target in cancer therapy. Cancer Med., 2013, 2(5), 662-673.
[http://dx.doi.org/10.1002/cam4.106] [PMID: 24403232]

Ishida, Y.; Agata, Y.; Shibahara, K.; Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J., 1992, 11(11), 3887-3895.
[http://dx.doi.org/10.1002/j.1460-2075.1992.tb05481.x] [PMID: 1396582]

Nishimura, H.; Nose, M.; Hiai, H.; Minato, N.; Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 1999, 11(2), 141-151.
[http://dx.doi.org/10.1016/S1074-7613(00)80089-8] [PMID: 10485649]

Carter, L.; Fouser, L.A.; Jussif, J.; Fitz, L.; Deng, B.; Wood, C.R.; Collins, M.; Honjo, T.; Freeman, G.J.; Carreno, B.M. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur. J. Immunol., 2002, 32(3), 634-643.
[http://dx.doi.org/10.1002/1521-4141(200203)32:3<634:AID-IMMU634>3.0.CO;2-9] [PMID: 11857337]

Freeman, G.J.; Long, A.J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L.J.; Malenkovich, N.; Okazaki, T.; Byrne, M.C.; Horton, H.F.; Fouser, L.; Carter, L.; Ling, V.; Bowman, M.R.; Carreno, B.M.; Collins, M.; Wood, C.R.; Honjo, T. Engagement of the PD-1 im-munoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 2000, 192(7), 1027-1034.
[http://dx.doi.org/10.1084/jem.192.7.1027] [PMID: 11015443]

Latchman, Y.; Wood, C.R.; Chernova, T.; Chaudhary, D.; Borde, M.; Chernova, I.; Iwai, Y.; Long, A.J.; Brown, J.A.; Nunes, R.; Greenfield, E.A.; Bourque, K.; Boussiotis, V.A.; Carter, L.L.; Carreno, B.M.; Malenkovich, N.; Nishimura, H.; Okazaki, T.; Honjo, T.; Sharpe, A.H.; Freeman, G.J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol., 2001, 2(3), 261-268.
[http://dx.doi.org/10.1038/85330] [PMID: 11224527]

Merck. Keytruda (Pembrolizumab) Prescribing Information Available from: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf Accessed on Jun 6, 2021).

Patnaik, A.; Kang, S.P.; Rasco, D.; Papadopoulos, K.P.; Elassaiss-Schaap, J.; Beeram, M.; Drengler, R.; Chen, C.; Smith, L.; Espino, G.; Ger-gich, K.; Delgado, L.; Daud, A.; Lindia, J.A.; Li, X.N.; Pierce, R.H.; Yearley, J.H.; Wu, D.; Laterza, O.; Lehnert, M.; Iannone, R.; Tolcher, A.W.; Phase, I. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res., 2015, 21(19), 4286-4293.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2607] [PMID: 25977344]

Ahamadi, M.; Freshwater, T.; Prohn, M.; Li, C.H.; de Alwis, D.P.; de Greef, R.; Elassaiss-Schaap, J.; Kondic, A.; Stone, J.A. Model-based characterization of the pharmacokinetics of pembrolizumab: A humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharm. Syst. Pharmacol., 2017, 6(1), 49-57.
[http://dx.doi.org/10.1002/psp4.12139] [PMID: 27863186]

Larkin, J.; Minor, D.; D’Angelo, S.; Neyns, B.; Smylie, M.; Miller, W.H., Jr; Gutzmer, R.; Linette, G.; Chmielowski, B.; Lao, C.D.; Lorigan, P.; Grossmann, K.; Hassel, J.C.; Sznol, M.; Daud, A.; Sosman, J.; Khushalani, N.; Schadendorf, D.; Hoeller, C.; Walker, D.; Kong, G.; Horak, C.; Weber, J. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in checkmate 037: A randomized, controlled, open-label phase III trial. J. Clin. Oncol., 2018, 36(4), 383-390.
[http://dx.doi.org/10.1200/JCO.2016.71.8023] [PMID: 28671856]

Sul, J.; Blumenthal, G.M.; Jiang, X.; He, K.; Keegan, P.; Pazdur, R. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist, 2016, 21(5), 643-650.
[http://dx.doi.org/10.1634/theoncologist.2015-0498] [PMID: 27026676]

Shu, C.A.; Rizvi, N.A. Into the clinic with nivolumab and pembrolizumab. Oncologist, 2016, 21(5), 527-528.
[http://dx.doi.org/10.1634/theoncologist.2016-0099] [PMID: 27026678]

Zheng, J.; Mehl, J.; Zhu, Y.; Xin, B.; Olah, T. Application and challenges in using LC-MS assays for absolute quantitative analysis of thera-peutic proteins in drug discovery. Bioanalysis, 2014, 6(6), 859-879.
[http://dx.doi.org/10.4155/bio.14.36] [PMID: 24702115]

Hoofnagle, A.N.; Wener, M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods, 2009, 347(1-2), 3-11.
[http://dx.doi.org/10.1016/j.jim.2009.06.003] [PMID: 19538965]

Ouyang, Z.; Furlong, M.T.; Wu, S.; Sleczka, B.; Tamura, J.; Wang, H.; Suchard, S.; Suri, A.; Olah, T.; Tymiak, A.; Jemal, M. Pellet digestion: A simple and efficient sample preparation technique for LC-MS/MS quantification of large therapeutic proteins in plasma. Bioanalysis, 2012, 4(1), 17-28.
[http://dx.doi.org/10.4155/bio.11.286] [PMID: 22191591]

Wild, D.; John, R.; Sheehan, C. The Immunoassay Handbook, Fourth Edi; Wild, D., Ed.; Elsevier, 2013.

Pandya, K.; Ray, C.A.; Brunner, L.; Wang, J.; Lee, J.W.; DeSilva, B. Strategies to minimize variability and bias associated with manual pipet-ting in ligand binding assays to assure data quality of protein therapeutic quantification. J. Pharm. Biomed. Anal., 2010, 53(3), 623-630.
[http://dx.doi.org/10.1016/j.jpba.2010.04.025] [PMID: 20483557]

Lee, J.W.; Kelley, M. Quality assessment of bioanalytical quantification of monoclonal antibody drugs. Ther. Deliv., 2011, 2(3), 383-396.
[http://dx.doi.org/10.4155/tde.10.99] [PMID: 22834008]

Ray, C.A.; Zhou, L.; Tsoi, J.; Uy, L.; Gu, J.; Malella, J.; Desimone, D.; Gunn, H.; Ma, M.; Lee, J.; DeSilva, B. A strategy for improving com-parability across sites for ligand binding assays measuring therapeutic proteins. J. Pharm. Biomed. Anal., 2010, 53(3), 729-734.
[http://dx.doi.org/10.1016/j.jpba.2010.04.022] [PMID: 20457502]

Yohrling, J. Ligand-binding assays: Risk of using a platform supported by a single vendor. Bioanalysis, 2009, 1(3), 629-636.
[http://dx.doi.org/10.4155/bio.09.46] [PMID: 21083158]

Basak, E.A.; Wijkhuijs, A.J.M.; Mathijssen, R.H.J.; Koolen, S.L.W.; Schreurs, M.W.J. Development of an enzyme-linked immune sorbent assay to measure nivolumab and pembrolizumab serum concentrations. Ther. Drug Monit., 2018, 40(5), 596-601.
[http://dx.doi.org/10.1097/FTD.0000000000000534] [PMID: 29847460]

Pluim, D.; Ros, W.; van Bussel, M.T.J.; Brandsma, D.; Beijnen, J.H.; Schellens, J.H.M. Enzyme linked immunosorbent assay for the quantifi-cation of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. J. Pharm. Biomed. Anal., 2019, 164, 128-134.
[http://dx.doi.org/10.1016/j.jpba.2018.10.025] [PMID: 30368118]

Yuan, L.; Arnold, M.E.; Aubry, A.F.; Ji, Q.C. Simple and efficient digestion of a monoclonal antibody in serum using pellet digestion: Com-parison with traditional digestion methods in LC-MS/MS bioanalysis. Bioanalysis, 2012, 4(24), 2887-2896.
[http://dx.doi.org/10.4155/bio.12.284] [PMID: 23244280]

Bronsema, K.J.; Bischoff, R.; van de Merbel, N.C. Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2012, 893-894, 1-14.
[http://dx.doi.org/10.1016/j.jchromb.2012.02.021] [PMID: 22426285]

Pan, S.; Aebersold, R.; Chen, R.; Rush, J.; Goodlett, D.R.; McIntosh, M.W.; Zhang, J.; Brentnall, T.A. Mass spectrometry based targeted pro-tein quantification: Methods and applications. J. Proteome Res., 2009, 8(2), 787-797.
[http://dx.doi.org/10.1021/pr800538n] [PMID: 19105742]

van den Broek, I.; Niessen, W.M.A.; van Dongen, W.D. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2013, 929, 161-179.
[http://dx.doi.org/10.1016/j.jchromb.2013.04.030] [PMID: 23685427]

Chiu, H.H.; Liao, H.W.; Shao, Y.Y.; Lu, Y.S.; Lin, C.H.; Tsai, I.L.; Kuo, C.H. Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy us-ing LC-MS/MS. Anal. Chim. Acta, 2018, 1019, 93-102.
[http://dx.doi.org/10.1016/j.aca.2018.02.040] [PMID: 29625688]

Iwamoto, N.; Hamada, A.; Shimada, T. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. Anal. Biochem., 2018, 540-541, 30-37.
[http://dx.doi.org/10.1016/j.ab.2017.11.002] [PMID: 29128290]

Rudek, M.A.; Chau, C.H.; Figg, W.D. Handbook of anticancer pharmacokinetics and pharmacodynamics. In: Rudek, M.A.; Chau, C.H.; Figg, W.D.; McLeod, H.L., Eds. Cancer Drug Discovery and Development; Springer New York: New York, NY, 2014.

Shimizu, T.; Seto, T.; Hirai, F.; Takenoyama, M.; Nosaki, K.; Tsurutani, J.; Kaneda, H.; Iwasa, T.; Kawakami, H.; Noguchi, K.; Shimamoto, T.; Nakagawa, K. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tu-mors. Invest. New Drugs, 2016, 34(3), 347-354.
[http://dx.doi.org/10.1007/s10637-016-0347-6] [PMID: 27000274]

Ma, Y.; Fang, W.; Zhang, Y.; Yang, Y.; Hong, S.; Zhao, Y.; Xie, S.; Ge, J.; Zhou, H.; Zhao, H.; Zhang, L. KEYNOTE-032: A randomized phase I study of pembrolizumab in chinese patients with advanced non-small cell lung cancer. Oncologist, 2020, 25(8), 650-e1145.
[http://dx.doi.org/10.1634/theoncologist.2020-0067] [PMID: 32134163]

van Vugt, M.J.H.; Stone, J.A.; De Greef, R.H.J.M.M.; Snyder, E.S.; Lipka, L.; Turner, D.C.; Chain, A.; Lala, M.; Li, M.; Robey, S.H.; Kondic, A.G.; De Alwis, D.; Mayawala, K.; Jain, L.; Freshwater, T. Immunogenicity of pembrolizumab in patients with advanced tumors. J. Immunother. Cancer, 2019, 7(1), 212.
[http://dx.doi.org/10.1186/s40425-019-0663-4] [PMID: 31395089]

Elassaiss-Schaap, J.; Rossenu, S.; Lindauer, A.; Kang, S.P.; de Greef, R.; Sachs, J.R.; de Alwis, D.P. Using model-based “learn and confirm” to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial. CPT Pharmacometrics Syst. Pharmacol., 2017, 6(1), 21-28.
[http://dx.doi.org/10.1002/psp4.12132] [PMID: 27863143]

Li, H.; Yu, J.; Liu, C.; Liu, J.; Subramaniam, S.; Zhao, H.; Blumenthal, G.M.; Turner, D.C.; Li, C.; Ahamadi, M.; de Greef, R.; Chatterjee, M.; Kondic, A.G.; Stone, J.A.; Booth, B.P.; Keegan, P.; Rahman, A.; Wang, Y. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J. Pharmacokinet. Pharmacodyn., 2017, 44(5), 403-414.
[http://dx.doi.org/10.1007/s10928-017-9528-y] [PMID: 28573468]

Li, H.; Sun, Y.; Yu, J.; Liu, C.; Liu, J.; Wang, Y. Semimechanistically based modeling of pembrolizumab time-varying clearance using 4 lon-gitudinal covariates in patients with non-small cell lung cancer. J. Pharm. Sci., 2019, 108(1), 692-700.
[http://dx.doi.org/10.1016/j.xphs.2018.10.064] [PMID: 30423341]

Chatterjee, M.S.; Elassaiss-Schaap, J.; Lindauer, A.; Turner, D.C.; Sostelly, A.; Freshwater, T.; Mayawala, K.; Ahamadi, M.; Stone, J.A.; de Greef, R.; Kondic, A.G.; de Alwis, D.P. Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma. CPT Pharma. Syst. Pharmacol., 2017, 6(1), 29-39.
[http://dx.doi.org/10.1002/psp4.12140] [PMID: 27896938]

Hamid, O.; Robert, C.; Daud, A.; Hodi, F.S.; Hwu, W-J.; Kefford, R.; Wolchok, J.D.; Hersey, P.; Joseph, R.W.; Weber, J.S.; Dronca, R.; Gan-gadhar, T.C.; Patnaik, A.; Zarour, H.; Joshua, A.M.; Gergich, K.; Elassaiss-Schaap, J.; Algazi, A.; Mateus, C.; Boasberg, P.; Tumeh, P.C.; Chmielowski, B.; Ebbinghaus, S.W.; Li, X.N.; Kang, S.P.; Ribas, A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melano-ma. N. Engl. J. Med., 2013, 369(2), 134-144.
[http://dx.doi.org/10.1056/NEJMoa1305133] [PMID: 23724846]

Robert, C.; Ribas, A.; Wolchok, J.D.; Hodi, F.S.; Hamid, O.; Kefford, R.; Weber, J.S.; Joshua, A.M.; Hwu, W.J.; Gangadhar, T.C.; Patnaik, A.; Dronca, R.; Zarour, H.; Joseph, R.W.; Boasberg, P.; Chmielowski, B.; Mateus, C.; Postow, M.A.; Gergich, K.; Elassaiss-Schaap, J.; Li, X.N.; Iannone, R.; Ebbinghaus, S.W.; Kang, S.P.; Daud, A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014, 384(9948), 1109-1117.
[http://dx.doi.org/10.1016/S0140-6736(14)60958-2] [PMID: 25034862]

Ribas, A.; Puzanov, I.; Dummer, R.; Schadendorf, D.; Hamid, O.; Robert, C.; Hodi, F.S.; Schachter, J.; Pavlick, A.C.; Lewis, K.D.; Cranmer, L.D.; Blank, C.U.; O’Day, S.J.; Ascierto, P.A.; Salama, A.K.S.; Margolin, K.A.; Loquai, C.; Eigentler, T.K.; Gangadhar, T.C.; Carlino, M.S.; Agarwala, S.S.; Moschos, S.J.; Sosman, J.A.; Goldinger, S.M.; Shapira-Frommer, R.; Gonzalez, R.; Kirkwood, J.M.; Wolchok, J.D.; Egger-mont, A.; Li, X.N.; Zhou, W.; Zernhelt, A.M.; Lis, J.; Ebbinghaus, S.; Kang, S.P.; Daud, A. Pembrolizumab versus investigator-choice chemo-therapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol., 2015, 16(8), 908-918.
[http://dx.doi.org/10.1016/S1470-2045(15)00083-2] [PMID: 26115796]

Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C.U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A. Pem-brolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med., 2015, 372(26), 2521-2532.
[http://dx.doi.org/10.1056/NEJMoa1503093] [PMID: 25891173]

Turner, D.C.; Kondic, A.G.; Anderson, K.M.; Robinson, A.G.; Garon, E.B.; Riess, J.W.; Jain, L.; Mayawala, K.; Kang, J.; Ebbinghaus, S.W.; Sinha, V.; de Alwis, D.P.; Stone, J.A. Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and cata-bolic clearance. Clin. Cancer Res., 2018, 24(23), 5841-5849.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0415] [PMID: 29891725]

Bins, S.; Koolen, S.L.W.; Mathijssen, R.H.J. Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance-letter. Clin. Cancer Res., 2019, 25(10), 3192.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-0164] [PMID: 31092616]

Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; Carcereny, E.; Ahn, M-J.; Felip, E.; Lee, J-S.; Hellmann, M.D.; Hamid, O.; Goldman, J.W.; Soria, J-C.; Dolled-Filhart, M.; Rutledge, R.Z.; Zhang, J.; Lunce-ford, J.K.; Rangwala, R.; Lubiniecki, G.M.; Roach, C.; Emancipator, K.; Gandhi, L. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med., 2015, 372(21), 2018-2028.
[http://dx.doi.org/10.1056/NEJMoa1501824] [PMID: 25891174]

Chatterjee, M.; Turner, D.C.; Felip, E.; Lena, H.; Cappuzzo, F.; Horn, L.; Garon, E.B.; Hui, R.; Arkenau, H.T.; Gubens, M.A.; Hellmann, M.D.; Dong, D.; Li, C.; Mayawala, K.; Freshwater, T.; Ahamadi, M.; Stone, J.; Lubiniecki, G.M.; Zhang, J. Im, E.; De Alwis, D.P.; Kondic, A.G.; Fløtten, Ø. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann. Oncol., 2016, 27(7), 1291-1298.
[http://dx.doi.org/10.1093/annonc/mdw174] [PMID: 27117531]

Lisberg, A.; Cummings, A.; Goldman, J.W.; Bornazyan, K.; Reese, N.; Wang, T.; Coluzzi, P.; Ledezma, B.; Mendenhall, M.; Hunt, J.; Wolf, B.; Jones, B.; Madrigal, J.; Horton, J.; Spiegel, M.; Carroll, J.; Gukasyan, J.; Williams, T.; Sauer, L.; Wells, C.; Hardy, A.; Linares, P.; Lim, C.; Ma, L.; Adame, C.; Garon, E.B. A phase II study of pembrolizumab in EGFR-Mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J. Thorac. Oncol., 2018, 13(8), 1138-1145.
[http://dx.doi.org/10.1016/j.jtho.2018.03.035] [PMID: 29874546]

Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; O’Brien, M.; Rao, S.; Hotta, K.; Leiby, M.A.; Lubiniecki, G.M.; Shentu, Y.; Rangwala, R.; Brahmer, J.R. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med., 2016, 375(19), 1823-1833.
[http://dx.doi.org/10.1056/NEJMoa1606774] [PMID: 27718847]

Gadgeel, S.M.; Stevenson, J.P.; Langer, C.J.; Gandhi, L.; Borghaei, H.; Patnaik, A.; Villaruz, L.C.; Gubens, M.; Hauke, R.; Yang, J.C.H.; Sequist, L.V.; Bachman, R.; Saraf, S.; Raftopoulos, H.; Papadimitrakopoulou, V. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer, 2018, 125, 273-281.
[http://dx.doi.org/10.1016/j.lungcan.2018.08.019] [PMID: 30429032]

Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T.S.; Miller, M.L.; Rekhtman, N.; Moreira, A.L.; Ibrahim, F.; Bruggeman, C.; Gasmi, B.; Zappasodi, R.; Maeda, Y.; Sander, C.; Garon, E.B.; Merghoub, T.; Wolchok, J.D.; Schumacher, T.N.; Chan, T.A. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 2015, 348(6230), 124-128.

Shin, S.H.; Park, H.Y.; Im, Y.; Jung, H.A.; Sun, J.M.; Ahn, J.S.; Ahn, M.J.; Park, K.; Lee, H.Y.; Lee, S.H. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. Int. J. Cancer, 2019, 145(9), 2433-2439.
[http://dx.doi.org/10.1002/ijc.32235] [PMID: 30807641]

Green, M.R.; Monti, S.; Rodig, S.J.; Juszczynski, P.; Currie, T.; O’Donnell, E.; Chapuy, B.; Takeyama, K.; Neuberg, D.; Golub, T.R.; Kutok, J.L.; Shipp, M.A. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 2010, 116(17), 3268-3277.
[http://dx.doi.org/10.1182/blood-2010-05-282780] [PMID: 20628145]

Armand, P.; Shipp, M.A.; Ribrag, V.; Michot, J.M.; Zinzani, P.L.; Kuruvilla, J.; Snyder, E.S.; Ricart, A.D.; Balakumaran, A.; Rose, S.; Mos-kowitz, C.H. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J. Clin. Oncol., 2016, 34(31), 3733-3739.
[http://dx.doi.org/10.1200/JCO.2016.67.3467] [PMID: 27354476]

Chen, R.; Zinzani, P.L.; Fanale, M.A.; Armand, P.; Johnson, N.A.; Brice, P.; Radford, J.; Ribrag, V.; Molin, D.; Vassilakopoulos, T.P.; To-mita, A.; von Tresckow, B.; Shipp, M.A.; Zhang, Y.; Ricart, A.D.; Balakumaran, A.; Moskowitz, C.H. Phase II study of the efficacy and safe-ty of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J. Clin. Oncol., 2017, 35(19), 2125-2132.
[http://dx.doi.org/10.1200/JCO.2016.72.1316] [PMID: 28441111]

Zinzani, P.L.; Ribrag, V.; Moskowitz, C.H.; Michot, J.M.; Kuruvilla, J.; Balakumaran, A.; Zhang, Y.; Chlosta, S.; Shipp, M.A.; Armand, P. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood, 2017, 130(3), 267-270.
[http://dx.doi.org/10.1182/blood-2016-12-758383] [PMID: 28490569]

Plimack, E.R.; Bellmunt, J.; Gupta, S.; Berger, R.; Chow, L.Q.M.; Juco, J.; Lunceford, J.; Saraf, S.; Perini, R.F.; O’Donnell, P.H. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. Lancet Oncol., 2017, 18(2), 212-220.
[http://dx.doi.org/10.1016/S1470-2045(17)30007-4] [PMID: 28081914]

Bellmunt, J.; de Wit, R.; Vaughn, D.J.; Fradet, Y.; Lee, J-L.; Fong, L.; Vogelzang, N.J.; Climent, M.A.; Petrylak, D.P.; Choueiri, T.K.; Necchi, A.; Gerritsen, W.; Gurney, H.; Quinn, D.I.; Culine, S.; Sternberg, C.N.; Mai, Y.; Poehlein, C.H.; Perini, R.F.; Bajorin, D.F. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med., 2017, 376(11), 1015-1026.
[http://dx.doi.org/10.1056/NEJMoa1613683] [PMID: 28212060]

McDermott, D.F.; Lee, J.L.; Bjarnason, G.A.; Larkin, J.M.G.; Gafanov, R.A.; Kochenderfer, M.D.; Jensen, N.V.; Donskov, F.; Malik, J.; Poprach, A.; Tykodi, S.S.; Alonso-Gordoa, T.; Cho, D.C.; Geertsen, P.F.; Climent Duran, M.A.; DiSimone, C.; Silverman, R.K.; Perini, R.F.; Schloss, C.; Atkins, M.B. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with ad-vanced clear cell renal cell carcinoma. J. Clin. Oncol., 2021, 39(9), 1020-1028.
[http://dx.doi.org/10.1200/JCO.20.02363] [PMID: 33529051]

McDermott, D.F.; Lee, J-L.; Ziobro, M.; Suarez, C.; Langiewicz, P.; Matveev, V.B.; Wiechno, P.; Gafanov, R.A.; Tomczak, P.; Pouliot, F.; Donskov, F.; Alekseev, B.Y.; Shin, S.J.; Bjarnason, G.A.; Castellano, D.; Silverman, R.K.; Perini, R.F.; Schloss, C.; Atkins, M.B. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J. Clin. Oncol., 2021, 39(9), 1029-1039.
[http://dx.doi.org/10.1200/JCO.20.02365] [PMID: 33529058]

Seiwert, T.Y.; Burtness, B.; Mehra, R.; Weiss, J.; Berger, R.; Eder, J.P.; Heath, K.; McClanahan, T.; Lunceford, J.; Gause, C.; Cheng, J.D.; Chow, L.Q. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol., 2016, 17(7), 956-965.
[http://dx.doi.org/10.1016/S1470-2045(16)30066-3] [PMID: 27247226]

Chow, L.Q.M.; Haddad, R.; Gupta, S.; Mahipal, A.; Mehra, R.; Tahara, M.; Berger, R.; Eder, J.P.; Burtness, B.; Lee, S.H.; Keam, B.; Kang, H.; Muro, K.; Weiss, J.; Geva, R.; Lin, C.C.; Chung, H.C.; Meister, A.; Dolled-Filhart, M.; Pathiraja, K.; Cheng, J.D.; Seiwert, T.Y. Antitumor ac-tivity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J. Clin. Oncol., 2016, 34(32), 3838-3845.
[http://dx.doi.org/10.1200/JCO.2016.68.1478] [PMID: 27646946]

Cohen, E.E.W.; Soulières, D.; Le Tourneau, C.; Dinis, J.; Licitra, L.; Ahn, M-J.; Soria, A.; Machiels, J-P.; Mach, N.; Mehra, R.; Burtness, B.; Zhang, P.; Cheng, J.; Swaby, R.F.; Harrington, K.J.; Acosta-Rivera, M.; Adkins, D.R.; Aghmesheh, M.; Ahn, M-J.; Airoldi, M.; Aleknavicius, E.; Al-Farhat, Y.; Algazi, A.P.; Almokadem, S.; Alyasova, A.; Bauman, J.R.; Benasso, M.; Berrocal, A.; Bray, V.; Burtness, B.A.; Caponigro, F.; Castro, A.; Cescon, T.P.; Chan, K.; Chaudhry, A.; Chauffert, B.; Cohen, E.; Csoszi, T.; De Boer, J.P.; Delord, J-P.; Dietz, A.; Dinis, J.; Dupuis, C.; Digue, L.; Erfan, J.; Escobar Alvarez, Y.; Evans, M.; Fidler, M.J.; Forster, M.D.; Friesland, S.; Ganti, A.K.; Geoffrois, L.; Grant, C.; Gruenwald, V.; Harrington, K.; Hoffmann, T.; Horvai, G.; Inciura, A.; Jang, R.; Jankowska, P.; Jimeno, A.; Joseph, M.; Juarez Ramiro, A.; Karaszewska, B.; Kawecki, A.; Keilholz, U.; Keller, U.; Kim, S-B.; Kocsis, J.; Kotecki, N.; Kozloff, M.F.; Lambea, J.; Landherr, L.; Lantsu-khay, Y.; Lazarev, S.A.; Lee, L.W.; Le Tourneau, C.; Licitra, L.; Lifirenko, I.D.; Mach, N.; Martincic, D.; Matorin, O.V.; McGrath, M.; Ma-chiels, J-P.; Mehra, R.; Misiukiewicz, K.; Morris, J.C.; Mufazalov, F.F.; Niu, J.; Pamoorthy Srinivasan, D.; Perez Segura, P.; Rauch, D.; Ribei-ro, M.L.; Rodriguez, C.; Rolland, F.; Russo, A.; Ruzsa, A.; Sanches, F.; Shin, S-W.; Shtiveland, M.; Soulieres, D.; Soria, A.; Specenier, P.; Szekanecz, E.; Szota, J.; van Herpen, C.M.L.; Velez-Cortes, H.A.; Walsh, W.V.; Wilop, S.; Winterhalder, R.; Wojtukiewicz, M.; Wong, D.; Zandberg, D. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carci-noma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet, 2019, 393(10167), 156-167.
[http://dx.doi.org/10.1016/S0140-6736(18)31999-8] [PMID: 30509740]

Ho, W.J.; Mehra, R. Pembrolizumab for the treatment of head and neck squamous cell cancer. Expert Opin. Biol. Ther., 2019, 19(9), 879-885.
[http://dx.doi.org/10.1080/14712598.2019.1644315] [PMID: 31317798]

Imamura, C.K. Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties. Drug Metab. Pharmacokinet., 2019, 34(1), 14-18.
[http://dx.doi.org/10.1016/j.dmpk.2018.11.003] [PMID: 30606646]

Lindauer, A.; Valiathan, C.R.; Mehta, K.; Sriram, V.; de Greef, R.; Elassaiss-Schaap, J.; de Alwis, D.P. Translational pharmacokinet-ic/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab. CPT Pharmacometrics Syst. Pharmacol., 2017, 6(1), 11-20.
[http://dx.doi.org/10.1002/psp4.12130] [PMID: 27863176]

Li, N.; Hou, X.; Huang, S.; Tai, R.; Lei, L.; Li, S.; Abuliz, A.; Wang, G.; Yang, S. Biomarkers related to immune checkpoint inhibitors thera-py. Biomed. Pharmacother., 2022, 147, 112470.
[http://dx.doi.org/10.1016/j.biopha.2021.112470] [PMID: 35074251]

Capalbo, C.; Scafetta, G.; Filetti, M.; Marchetti, P.; Bartolazzi, A. Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The galectin-3 signature in NSCLCs. Int. J. Mol. Sci., 2019, 20(7), 1607.
[http://dx.doi.org/10.3390/ijms20071607] [PMID: 30935099]

Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.M.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; West, A.N.; Carmona, M.; Kivork, C.; Seja, E.; Cherry, G.; Gutierrez, A.J.; Grogan, T.R.; Mateus, C.; Tomasic, G.; Glaspy, J.A.; Emerson, R.O.; Robins, H.; Pierce, R.H.; Elashoff, D.A.; Robert, C.; Ribas, A. PD-1 blockade induces responses by inhibiting adaptive immune re-sistance. Nature, 2014, 515(7528), 568-571.
[http://dx.doi.org/10.1038/nature13954] [PMID: 25428505]

Rooney, M.S.; Shukla, S.A.; Wu, C.J.; Getz, G.; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cyto-lytic activity. Cell, 2015, 160(1-2), 48-61.
[http://dx.doi.org/10.1016/j.cell.2014.12.033] [PMID: 25594174]

Yarchoan, M.; Hopkins, A.; Jaffee, E.M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med., 2017, 377(25), 2500-2501.
[http://dx.doi.org/10.1056/NEJMc1713444] [PMID: 29262275]

McGranahan, N.; Furness, A.J.S.; Rosenthal, R.; Ramskov, S.; Lyngaa, R.; Saini, S.K.; Jamal-Hanjani, M.; Wilson, G.A.; Birkbak, N.J.; Hiley, C.T.; Watkins, T.B.K.; Shafi, S.; Murugaesu, N.; Mitter, R.; Akarca, A.U.; Linares, J.; Marafioti, T.; Henry, J.Y.; Van Allen, E.M.; Miao, D.; Schilling, B.; Schadendorf, D.; Garraway, L.A.; Makarov, V.; Rizvi, N.A.; Snyder, A.; Hellmann, M.D.; Merghoub, T.; Wolchok, J.D.; Shukla, S.A.; Wu, C.J.; Peggs, K.S.; Chan, T.A.; Hadrup, S.R.; Quezada, S.A.; Swanton, C. Clonal neoantigens elicit T cell immuno-reactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351(6280), 1463-1469.

Gibney, G.T.; Weiner, L.M.; Atkins, M.B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol., 2016, 17(12), e542-e551.
[http://dx.doi.org/10.1016/S1470-2045(16)30406-5] [PMID: 27924752]

Graves, M. CelliMarchett, G.; van Zyl, B.; Tang, D.; Vilain, R.E.; van der Westhuizen, A.; Bowden, N.A. Monitoring patient response to pembrolizumab with peripheral blood exhaustion marker profiles. Front. Med., 2019, 6, 113.

Soyano, A.E.; Dholaria, B.; Marin-Acevedo, J.A.; Diehl, N.; Hodge, D.; Luo, Y.; Manochakian, R.; Chumsri, S.; Adjei, A.; Knutson, K.L.; Lou, Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibod-ies. J. Immunother. Cancer, 2018, 6(1), 129.
[http://dx.doi.org/10.1186/s40425-018-0447-2] [PMID: 30470260]

Costantini, A.; Takam Kamga, P.; Julie, C.; Corjon, A.; Dumenil, C.; Dumoulin, J.; Ouaknine, J.; Giraud, V.; Chinet, T.; Rottman, M.; Emile, J.F.; Giroux Leprieur, E. Plasma biomarkers screening by multiplex ELISA assay in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Cancers (Basel), 2020, 13(1), 1-12.
[http://dx.doi.org/10.3390/cancers13010097] [PMID: 33396187]

Awada, G.; Jansen, Y.; Schwarze, J.K.; Tijtgat, J.; Hellinckx, L.; Gondry, O.; Vermeulen, S.; Warren, S.; Schats, K.; van Dam, P.J.; Kockx, M.; Keyaerts, M.; Everaert, H.; Seremet, T.; Rogiers, A.; Neyns, B. A comprehensive analysis of baseline clinical characteristics and bi-omarkers associated with outcome in advanced melanoma patients treated with pembrolizumab. Cancers (Basel), 2021, 13(2), 1-18.
[http://dx.doi.org/10.3390/cancers13020168] [PMID: 33418936]

Ribas, A.; Robert, C.; Hodi, F.S.; Wolchok, J.D.; Joshua, A.M.; Hwu, W-J.; Weber, J.S.; Zarour, H.M.; Kefford, R.; Loboda, A.; Albright, A.; Kang, S.P.; Ebbinghaus, S.; Yearley, J.; Murphy, E.; Nebozhyn, M.; Lunceford, J.K.; McClanahan, T.; Ayers, M.; Daud, A. Association of response to Programmed Death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an Interferon-inflammatory immune gene signature. J. Clin. Oncol., 2015, 33(15)(Suppl.), 3001-3001.
[http://dx.doi.org/10.1200/jco.2015.33.15_suppl.3001]

Freshwater, T.; Kondic, A.; Ahamadi, M.; Li, C.H.; de Greef, R.; de Alwis, D.; Stone, J.A. Evaluation of dosing strategy for pembrolizumab for oncology indications. J. Immunother. Cancer, 2017, 5(1), 43.
[http://dx.doi.org/10.1186/s40425-017-0242-5] [PMID: 28515943]

Ogungbenro, K.; Patel, A.; Duncombe, R.; Nuttall, R.; Clark, J.; Lorigan, P. Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis. Clin. Pharmacol. Ther., 2018, 103(4), 582-590.
[http://dx.doi.org/10.1002/cpt.875] [PMID: 28913853]

Lala, M.; Li, T.R.; de Alwis, D.P.; Sinha, V.; Mayawala, K.; Yamamoto, N.; Siu, L.L.; Chartash, E.; Aboshady, H.; Jain, L. A six-weekly dos-ing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur. J. Cancer, 2020, 131, 68-75.
[http://dx.doi.org/10.1016/j.ejca.2020.02.016] [PMID: 32305010]

Georgieva, M.; da Silveira Nogueira Lima, J.P.; Aguiar, P., Jr; de Lima Lopes, G., Jr; Haaland, B. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. Lung Cancer, 2018, 124, 248-254.
[http://dx.doi.org/10.1016/j.lungcan.2018.08.018] [PMID: 30268469]

Hu, X.; Hay, J.W. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. Lung Cancer, 2018, 123, 166-171.
[http://dx.doi.org/10.1016/j.lungcan.2018.07.012] [PMID: 30089590]

Huang, M.; Lou, Y.; Pellissier, J.; Burke, T.; Liu, F.X.; Xu, R.; Velcheti, V. Cost effectiveness of pembrolizumab vs. standard-of-care chemo-therapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States. PharmacoEconomics, 2017, 35(8), 831-844.
[http://dx.doi.org/10.1007/s40273-017-0527-z] [PMID: 28620848]

Neumann, P.J.; Cohen, J.T.; Weinstein, M.C. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N. Engl. J. Med., 2014, 371(9), 796-797.
[http://dx.doi.org/10.1056/NEJMp1405158] [PMID: 25162885]

Chouaid, C.; Bensimon, L.; Clay, E.; Millier, A.; Levy-Bachelot, L.; Huang, M.; Levy, P. Cost-effectiveness analysis of pembrolizumab ver-sus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer, 2019, 127, 44-52.
[http://dx.doi.org/10.1016/j.lungcan.2018.11.008] [PMID: 30642550]

Peer, C.J.; Goldstein, D.A.; Goodell, J.C.; Nguyen, R.; Figg, W.D.; Ratain, M.J. Opportunities for using in silico-based extended dosing regi-mens for monoclonal antibody immune checkpoint inhibitors. Br. J. Clin. Pharmacol., 2020, 86(9), 1769-1777.
[http://dx.doi.org/10.1111/bcp.14369] [PMID: 32424951]